Context
Wandercraft is offering back mobility to impaired person. The company is at the cross-roads of AI and Robotics and HealthTech. It has taken exoskeletons to the next level with a rare combination of deep tech robotics built around AI and proprietary motion algorithms allowing the company to bring the first self-balanced exoskeleton to the market. Having started to sell into the rehabilitation market, Wandercraft’s ultimate target is the replacement of the wheelchair with a commercial and affordable personal mobility solution. Exoskeletons have the potential to change for the better the lives of millions of people
Most of this new round of financing will be used by Wandercraft to fulfil the company’s mission of “mobility for all”, through the continued development, then launch, of the new Personal Exoskeleton for outdoor and home use. The funding will also allow Wandercraft to accelerate the deployment of Atalante, its pioneering CE marked rehabilitation exoskeleton, in the US
About Wandercraft
Wandercraft was founded in 2012. A group of engineers refused to accept the status quo of wheelchair use, believing they could create a better solution for mobility and autonomy. Wandercraft builds autonomous walking exoskeletons. Its first version, Atalante, was commercialized in 2019 and is used by rehabilitation and neurological hospitals in Europe and North America. Atalante provides innovative care for many patients based on realistic, hands-free, crutch-free locomotion.
Wandercraft is developing a personal version of the exoskeleton for outdoor and home use. It will enable people with reduced mobility to regain autonomy in their daily activities and improve their health, both at home and elsewhere.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Sole Financial Advisor to Wandercraft on its $45 million Fundraising
Bryan, Garnier & Co acted as Sole Financial Advisor to Wandercraft, successfully completing this $45m fundraising led by the US fund Quadrant Management, providing healthcare and scale-up expertise in the US, joined by existing investor Bpifrance, a long-standing growth partner in France and new participants MACSF, Malakoff Humanis, AG2R La Mondiale, Mutuelles Impact and Sofiouest. Other existing investors Xange, IDinvest, LBO France and Cemag Invest continued to support the company and participated to the round
This transaction is a strong testimony of Bryan Garnier’s team credentials within the HealthTech industry and gives further evidence of Bryan Garnier’s DNA to back talented entrepreneurs and industry-defining companies that are shaping new industrial boundaries
The process targeted more than 450 investors including Venture Capital, family offices and strategic investors in healthcare and technology across US, Europe, and Asia
Bryan, Garnier & Co’s deep healthcare and technology industry expertise, combined with 20 years of experience in arranging financing for growth-stage businesses, enabled Wandercraft to secure an optimal transaction to drive its commercial scale-up and operational development
Share